What I am working with: a 25G drawing needle · 20 mg/mL.
The units are where I keep going wrong, so please be explicit about them.
I have sanity-checked the order of magnitude and it seems right, which is not the same as being right.
Where is my error, and what is the correct working?
At 20 mg/mL every microlitre left behind is 20 µg, so a 50 µL hub costs 1 mg per draw and a 5 µL fixed-needle barrel costs 0.1 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 10 mg gone, which at 20 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 50 per cent; against a 0.25 mg dose it is 400 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 25G drawing needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
The distinction that resolves most of these questions is understanding that dead space is a fixed volume — typically 3 to 5 µL in a fixed-needle syringe and 35 to 100 µL in a luer-lock — and its cost scales with how small your draws are.
At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.
| Vial | Diluent | Concentration | 0.25 mg | 0.5 mg | 1 mg | 2.5 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 5 mg | 2 mL | 2.5 mg/mL | 10 u | 20 u | 40 u | 100 u |
| 10 mg | 1 mL | 10 mg/mL | 2.5 u | 5 u | 10 u | 25 u |
| 10 mg | 2 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 10 mg | 3 mL | 3.33 mg/mL | 7.5 u | 15 u | 30 u | 75 u |
Units are U-100 insulin units, where 1 unit = 0.01 mL. Divide dose by concentration for millilitres, then multiply by 100.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
If cost matters, this is the first thing to change, not the last.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsPut another way, a fixed-needle insulin syringe holds roughly 3 to 5 µL dead space and costs the same as a luer-lock syringe with 35 to 100 µL dead space.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
More usefully, the luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.
I would not underestimate the dead-space cost when calculating your true cost per dose.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
More usefully, this is arithmetic, so let us do the arithmetic and see where the losses actually are.
The needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.
Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
The switch nearly doubles your vial, which is better than most other optimisations combined.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.